sellWeak
Deborah Knobelman sold $22k of KRON
President & Interim CEO at Kronos Bio, Inc.. 24,838 shares at an average of $0.87, traded Jun 5, 2025, filed Jun 6, 2025.
Warning score
30Value
$22k
24,838 shares
Holdings after
139,422
-15% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$22k at market
- +5Share of holdings soldSold 15% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-016003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2025 | SOpen-market sale Common Stock | -24,838 | $0.87 | $22k | 139,422 | Jun 6, 2025 |
Related signals
Other insiders at Kronos Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $734k 615,518 shares | +6% | |
| 60Notable | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $3.1M 3,005,122 shares | +69% | |
| 30Weak | Kronos Bio, Inc. | Allison Frisbee SR VP, CORP OPERATIONS & LEGAL | $13k 12,105 shares | -6% | |
| 30Weak | Kronos Bio, Inc. | Charles Y Lin SR VP, RESEARCH & DEVELOPMENT | $13k 12,036 shares | -5% | |
| 30Weak | Kronos Bio, Inc. | Elizabeth A Olek SR VP, CLINICAL SCIENCE | $7,765 7,368 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $14k 12,009 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $8,718 7,366 shares | -3% | |
| 35Weak | Kronos Bio, Inc. | Barbara Kosacz COO & General Counsel | $13k 10,676 shares | -1% | |
| 23Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $23k 17,367 shares | -5% | |
| 23Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $13k 10,032 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.